Scarica l'app Stockscreener
2.37
0.42%
0.01
Armata Pharmaceuticals Inc Borsa (ARMP) Ultime notizie
Armata Pharmaceuticals announces executive departure - Investing.com
Arkema S.A. (OTCMKTS:ARKAY) Sees Large Growth in Short Interest - MarketBeat
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Confronting Oropouche: a new stage for Cuban science - Radio Cadena Agramonte
Alto Neuroscience's Market Cap Drops To US$358m Leaving Insiders With Losses - Simply Wall St
American Century Companies Inc. Purchases 8,841 Shares of Armstrong World Industries, Inc. (NYSE:AWI) - MarketBeat
The Attractiveness of Investing In Artiva Biotherapeutics Inc (ARTV) is Growing - Knox Daily
ANRO’s latest rating updates from top analysts. - Knox Daily
ARKO Corp. (ARKO) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Art’s-Way Manufacturing (NASDAQ:ARTW) Now Covered by StockNews.com - Defense World
Dimensional Fund Advisors LP Has $193.14 Million Position in Archrock, Inc. (NYSE:AROC) - Defense World
Your Safety First: What You Need to Know About Bionpharma’s Urgent Atovaquone Recall - MyChesCo
Building Materials Stocks Q2 Results: Benchmarking Armstrong World (NYSE:AWI) - Yahoo Finance
Aurora Biosynthetics launch set to revolutionise RNA Therapeutics - Manufactures Monthly
Amplia Therapeutics’ Drug Fast-Tracked by FDA - TipRanks
Atovaquone Oral Suspension Recall Issued Due to Bacterial Contamination Risks - AboutLawsuits.com
Burgundy Asset Management Ltd. Purchases 17,075 Shares of Armstrong World Industries, Inc. (NYSE:AWI) - MarketBeat
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023 - GuruFocus.com
New player in RNA manufacturing: Aurora Biosynthetics launches in Australia - Australian Manufacturing
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 11.1% in August - MarketBeat
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Quantisnow
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 133.3% in August - MarketBeat
Armata Pharmaceuticals Updates Progress and Corporate Presentation - TipRanks
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium - Longview News-Journal
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium - PR Newswire
ARMP Stock Earnings: Armata Pharmaceuticals Beats EPS for Q2 2024 - MSN
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Down 12.9% in July - MarketBeat
Dr. Deborah Birx Is Now The CEO Of Armata Pharmaceuticals - KossyDerrick
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Rating Reiterated by HC Wainwright - Defense World
HC Wainwright Brokers Raise Earnings Estimates for Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) - Defense World
HC Wainwright Analysts Boost Earnings Estimates for Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) - MarketBeat
Armata Pharmaceuticals' (ARMP) Buy Rating Reiterated at HC Wainwright - MarketBeat
Armata Pharmaceuticals Welcomes David House as New SVP of Finance - TipRanks
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - Quantisnow
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - PR Newswire
ARMPArmata Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
ARMP Stock Earnings: Armata Pharmaceuticals Beats EPS for Q2 2024 - InvestorPlace
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update - StockTitan
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update - PR Newswire
10 Best Healthcare Stocks to Invest In (August 2024) - Securities.io
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 2.8% - MarketBeat
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - PR Newswire
Innoviva’s (INVA) Stock Is Thriving With Strategic Investments Pay-Off - MSN
Armata Pharmaceuticals Adjusts Executive Compensation By Investing.com - Investing.com Nigeria
Armata Pharmaceuticals Adjusts Executive Compensation - Investing.com
Bacteriophage Therapy Market Future Business Opportunities - openPR
Staphylococcus aureus Bacteremia Treatment Market 2032: FDA - openPR
Bacteriophage Medicine Market 2034 | Key Brands -Life Extension, Arthur Andrew Medical, ADM., Biochimpharm, Micreos Huma – KnowCasino - KnowCasino
Bacteriophage Therapy Market Overall Study Report 2024-2031 | - openPR
Corner Growth Acquisition Corp. 2 (NASDAQ:TRONW) Sees Large Growth in Short Interest - American Banking and Market News
Grayscale Digital Large Cap Fund LLC (OTCMKTS:GDLC) Short Interest Update - American Banking and Market News
Odyssey Marine sets executive bonus plan linked to lawsuit outcome By Investing.com - Investing.com India
Winmill & Co. buys Bexil Investment Trust shares worth over $55k By Investing.com - Investing.com
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Receives Buy Rating from HC Wainwright - Defense World
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update - MarketBeat
Cystic Fibrosis Market is Projected to Boost by 2034, Predicts DelveInsight | Key CompaniesVerona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech, Aridis Pharmaceuticals, BiomX, Inc., Boehringer Ingelheim - India Shorts
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Earns Buy Rating from HC Wainwright - MarketBeat
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection – Company Announcement - Financial Times
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infe - StreetInsider.com
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PR Newswire
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 - Quantisnow
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 - Financial Times
Chronic Pulmonary Infections Pipeline 2024: Clinical Trials - openPR
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 - PR Newswire
Bacteriophage Market SWOT and PESTAL Analysis | 2032 - WICZ
SeaCrest Wealth Management LLC Has $137,000 Holdings in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) - Defense World
Phage Therapy Market Research Report 2024 -NPO Microgen, Proteon Pharmaceuticals, Phagelux, Intralytix, Micreos, Eliava – KnowCasino - KnowCasino
0.05%
4.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):